Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.

摘要: Epidermal growth factor receptors (EGFR) play an im-portant role in the development and progression of many solid tumours. Numerous cell functions, such as proliferation, differentiation angiogenesis, depend on EGFR activation. Moreover, is over-expressed tumours (e.g. up to 80% colorectal cancer 93% non-small-cell lung cancer) important target structure tumour therapy patients refractory or intolerant chemotherapy. The chimeric EGFR-blocking monoclonal antibody cetuximab, fully human pani-tumumab, low-molecular weight tyrosine kinase inhibitors gefitinib erlotinib are most frequently used inhibitors. As also expressed normal epidermis, sweat glands, sebaceous glands outer root sheath hair follicle, cuta-neous side-effects encountered during its therapeutic blockade. Acneiform skin reactions common, but xerosis, nail changes have been described (1–3).We report here case a 43-year-old woman who developed clinically distinct, yellowish papular eruption within borders otherwise typical acneiform her cheeks sporadically chest treatment change from cetuximab panitumumab. CASE REpoRT